A New Approach Enabling Physicians to Treat Toenail Fungus at the Point-of-Care HSG 42 is highly differentiated. It is ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 ...
PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage ...
News-Medical.Net on MSN
AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and Drug Administration (FDA) has accepted ...
The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results